Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Vomiting 2Uterine Cervical Neoplasms 2Nausea 2Condylomata Acuminata 2Breast Neoplasms 2Sezary Syndrome 1Renal Insufficiency 1Osteoarthritis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Kidney Failure, Chronic 1Cancer Pain 1Bone Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14Vaccines, Synthetic 10Papillomavirus Vaccines 6Vaccines 5Imiquimod 4Trichloroacetic Acid 3Gels 3green tea extract polyphenone E 2Podophyllin 2Human Papillomavirus Recombinant Vaccine nonavalent 2Ethanol 2Duration of Therapy 2Cryotherapy 2Cantharidin 2ranpirnase 1polyphenon E 1nanocurcumin 1human papillomavirus vaccine, L1 type 16, 18 1hecolin 1berdazimer sodium 1Zinc 1Viusid 1Vaccination 1VP-102 1Tuberculin 1Therapies, Investigational 1Tea 1PRA1 protein, Candida albicans 1Omiganan 1Ointments 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Condylomata Acuminata × Duration of Therapy × Clear all
NCT00092482 2017-03-22

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
3,882 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00517309 2017-03-22

FUTURE

Merck Sharp & Dohme LLC

Phase 3 Completed
1,877 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡